Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 1, 2024Journal of Clinical Oncology

Lessons learned in migrating from one commercial genetics decision-support tool to another: Assessment of data integrity and utilization readiness.

View Full Paper
Ask AI
Bookmark
Share

Authors

CLCalvin LeUniversity of WashingtonKTKevin TatunayFred Hutch Cancer CenterMLMercy LaurinoFred Hutch Cancer Center

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Le et al. (2024) studied this question.

synapsesocial.com/papers/68e66f03b6db6435875fa1c1https://doi.org/10.1200/jco.2024.42.16_suppl.e23232
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Characterizing trends in clinical genetic testing: A single-center analysis of EHR data from 1.8 million patients over two decades2025 · 13 citations
  2. 2Streamlining Inherited Cancer Identification via an EMR-Integrated Risk Assessment Platform2026
  3. 3Developing the MyCancerGene Digital Health Portal to Improve Patients’ Understanding of Germline Cancer Genetic Test Results: Development, User, and Usability Testing Study2024 · 1 citations
  4. 4Enhancing cancer risk identification through a digital genetic risk assessment tool.2025
  5. 5Evaluating a hybrid AI-powered digital health guide to improve informed decision making and streamline access to genetic testing for hereditary cancer.2026